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Abstract
Background: Drug-induced resistance is one the major obstacles that may lead to
therapeutic failure during cancer treatment. Different genetic alterations occur when
tumor cells divide. Among new generations of tumor cells, some may express intrinsic
resistance to a specific chemotherapeutic agent. Also, some tumor cells may carry a
gene that can develop resistance induced by the therapeutic drug. The methods by
which the therapeutic approaches need to be revised in the occurrence of drug
induced resistance is still being explored. Previously, we introduced a model that
expresses only intrinsic drug resistance in a conjoint normal-tumor cell setting. The
focus of this work is to expand our previously reported model to include terms that
can express both intrinsic drug resistance and drug-induced resistance. Additionally, we
assess the response of the cell population as a function of time under different
treatment strategies and discuss the outcomes.
Methods: The model introduced is expressed in the format of coupled differential
equations which describe the growth pattern of the cells. The dynamic of the cell
populations is simulated under different treatment cases. All computational simulations
were executed using Mathematica v7.0.
Results: The outcome of the simulations clearly demonstrates that while some
therapeutic strategies can overcome or control the intrinsic drug resistance, they may
not be effective, and are even to some extent damaging, if the administered drug
creates resistance by itself.
Conclusion: In the present study, the evolution of the cells in a conjoint setting, when
the system expresses both intrinsic and induced resistance, is mathematically modeled.
Followed by a set of computer simulations, the different growing patterns that can be
created based on choices of therapy were examined. The model can still be improved
by considering other factors including, but not limited to, the nature of the cancer
growth, the level of toxicity that the body can tolerate, or the strength of the patient’s
immune system.
Keywords: Cancer modeling, Conjoint cell growth, Chemotherapy, Drug resistance,
Mutation
Background
The mechanism under which different types of cancers progress is complex. This
progression depends on many factors including, but not limited to, the growth rate of
cells, mutual interaction of cancer cells with surrounding normal cells, the way in
which they are affected by immune system, and their response to anti-cancer treatment
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strategies. It also depends upon the mutations that may happen during cell division,
leading into the inapplicability of chemotherapeutic treatments.
The most common therapeutic approach to reduce the population of cancer cells and
control their progression is chemotherapy. However, on many occasions, the success of
this treatment is barred as a result of ineffectiveness of the drug used, which is known as
drug resistance [1]. Some of the factors that can contribute to the creation of drug resis-
tance are related to the drug delivery defects, insufficient drug activation at the tumor site,
or the resistance that results from genetic mutation of the tumor cells [2, 3]. Given the
importance of implementing the best therapeutic strategy, detecting any pre-existing drug
resistance, or any resistance induced by the drug during a course of chemotherapy, is
important as it provides insight into the way in which the chemotherapeutic approach
needs to be modified [4].
Cancer cells constantly divide into new generations of cancerous cells. Some of the
newly born cells may contain mutated genes that express resistance to anticancer
drugs, while the rest can still be susceptible to the therapy. This type of drug resistance
is known as intrinsic resistance. A variety of approaches are being implemented to
overcome the development of intrinsic drug resistance, including the uses of very high
doses of chemotherapy, or utilizing combination therapies [5]. However, the success of
chemotherapeutic treatments is less probable in cases when the implemented drug
induces drug resistance. For example, some works show that in the case of drug in-
duced resistance, it takes only few days for a tumor to regrow after the appearance of
the resistance [6]. In some types of cancers, such as non-small cell lung cancer
(NSCLC), a high percentage of patients develop drug resistance after long-term drug
administration. In NSCLC, this kind of drug resistance is associated with a new set of
mutations (T790M) created among wild cancerous tumor cells exposed to the specific
chemotherapeutic agent. In such cancers, while the drug-responsive tumor cells shrink,
the mutated tumor cells become resistant to the therapy; therefore, they grow and form
a new tumor that no longer is responsive to the treatment [7].
An effective adjustment to a therapeutic approach is tied to a close monitoring of the
evolution of untreated and treated normal and cancer cells, and the detection of any
sign of resistance that may occur during the term of therapy. Modeling the evolution of
the system has attracted more attention as it can provide insight into the progression
of the diseases under a specific treatment; therefore, it is considered a parallel tool for
tailoring the therapeutic approaches.
The various models expressed the growth of untreated normal and tumor cells with
their possible interactions [8–12]. These models were then expanded to evaluate the
dynamic of the system when different therapeutic approaches, including chemotherapy,
viro-therapy, radiation, and immunotherapy, were utilized. Also, some models have
mathematically and numerically examined different cases in which some level of drug
resistance exists in the system [13–23]. The evolution of different types of cancer cells
in a multi-resistance setting under chemotherapeutic treatment is not well considered
in previous researches.
The aim of the present study is to construct a new model to improve biological
reliability, and to enable the evaluation of the conditions in which the special chemo-
therapeutic drug can contribute to the treatment of cancer or cause more damage
during the treatment by including drug resistance.
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This paper focuses on simulating the evolution of different types of cancer cells in a
multi-resistance setting under chemotherapeutic treatment.
Methods
Conjoint core model in an intrinsic chemo-resistance setting
In a conjoint setting, normal and tumor cells interact with one another during
their growth. This mutual interaction between normal and tumor cells has been
biologically detected and was initially modeled by Witten [8, 9]. In our previous
work, we modified this core model to include the resistance that tumor cells may
express against chemotherapeutic agents. To set this modification, we first consid-
ered that the control of normal cells over the growth of tumor cells is negligible,
as it is large tumor cells that mainly express resistance to the treatment. We then
included a second group of tumor cells in the core model. We assumed that this
new group of tumor cells would be created during cell division and would carry a
mutated gene that causes intrinsic resistance against a specific type of chemothera-
peutic agent. Further, we assumed that this group of tumor cells would also grow
under the logistic growth law. This model can be analyzed in the presence of a
specific anti-cancer agent, where the population of drug-responsive tumor cells is
reduced as a result of the interaction with the drug. The dynamic of the compo-
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where N(t), T(t), TR(t) are respectively the total number of normal cells, drug-
responsive tumor cells, and drug-resistant tumor cells with the unit of cells. Also,
KN, KT, KR are the carrying capacity of normal cells and two types of tumor cells
with the unit of cells. The per capita growth rate for the drug-responsive tumor
cells, drug-resistant tumor cells, and normal cells are expressed by rT, rR, rN with
the unit of time−1. The T* is the critical size of the collection of tumor cells with
the unit of cells. The second term in equation 1c represents the interaction be-
tween tumor and normal cells. In this term κ has the units of time−1. The drug-
responsive tumor cells become intrinsically resistant tumor cells with a mutation
rate of τ (time−1). The last term in eq. 1a and 1c represents the interaction of nor-
mal and drug-responsive tumor cells with chemotherapeutic drugs. These cells die
due to drug toxicity. The response function to the chemotherapeutic drug can be
structured as ai(1-e
MC), where M is associated to the drug pharmacokinetics and
known as the drug efficiency coefficient with the unit of m2.mg−1, and C repre-
sents the amount of the drug at the tumor site (mg. m−2). The coefficient ai when
(1c)
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i = N, T with the unit of time−1 expresses the rate of chemotherapy-induced death
[18, 24].
To achieve a more complete picture of the evolution of the cells in a drug resistance
setting, the current model is modified below to include those types of drug resistance
created as a result of interaction with chemotherapeutic agents.
Conjoint core model and drug-induced resistance and simulations
Extended model
A group of tumor cells with specific mutated genes may develop resistance to chemother-
apeutic agents as they interact with the drug. To introduce this type of the drug resistance
in our model, three groups of tumor cells were considered. As explained before, the first
group are tumor cells that are responsive to the drug and grow under the logistic law, and
their population decreases as they interact with the drug. The drug-sensitive tumor cells
create a new generation of tumor cells as they divide. We assume that the newly born
tumor cells can be placed in one of the following three groups. The first group includes
those that are still responsive to the administered drug, and are known as wild tumor
cells, T. The second group is those tumor cells that are still responsive to the drug, but
carry a mutated gene that causes drug resistance as they interact with the introduced
drug. These tumor cells are placed in the category of mutated tumor cells, TM. The third
group of tumor cells is those that are not responsive to the drug and intrinsically resist
the administered drug. This group is identified by TR. All of these tumor cells are assumed
to grow under the logistic law. The term τ1T(t) in equations 1a and 1b expresses the tran-
sition of wild tumor cells to resistant tumor cells. The newly introduced term τ2T(t) in
equations 2a and 2c represents the transition of wild tumor cells to mutated tumor
cells. Also, the toxic effect of the administered drug, which leads to the reduction
in populations of cells, has been expressed by aT(1-e
MC)T on wild tumor cells as
well [24]. The interaction of the drug with the mutated tumor cells partially kills
them and partially turns them into drug-resistant tumor cells. The toxic effect of
the drug which leads to the reduction of the population of mutated tumor cells
has been expressed as aTM (1-e
MC)TM, where aTM is the killing rate of mutated
tumor cells induced by the first administered drug. Also, we considered that the
mutated tumor cells also follow the logistic growth. Therefore, KM and rM are the
carrying capacity of the mutated tumor cells and per capita growth rate of this
group of tumor cells, respectively. The term that expresses the conversion of mutated
tumor cells to drug-resistant in equations 2b and 2c has been expressed by τM→ R(1 − e
−
MC)TM. In this term τM→ R with the unit of time
−1 expresses the conversion rate of mu-
tated tumor cells to resistant tumor cells due to interaction with the drug.
Furthermore, to evaluate cases that undergo combination therapy, a second chemo-
therapeutic drug can be added to the treatment, in the way that this second drug can
be effective on drug-resistant tumor cells and can be mathematically introduced as aTR
1−e−MC2ð ÞTR (equation 2b). In the following equations, aT, and aTM, are the death rate
induced by the first administered chemotherapeutic drug, while aTR is the death rate of
the tumor resistance cells induced by this second drug. In addition, the concentration
of the second drug is introduced by C2.
The schematic view of the system interactions is expressed in Fig. 1.
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Numerical simulations and choice of parameters
To evaluate the dynamic of the cells, different cases and therapeutic approaches have
been analyzed through a series of numerical simulations and under various treatment
approaches. Table 1 expresses the values of parameters in each of the treatment
strategies that has been numerically evaluated below.
The set of equations introduced above (2a-2d) shows the population dynamic of four
variables (T, TR, TM, N). The terms of these equations and associated parameters
describe the growth of each introduced population of the cells, or the way that they are
affected as a result of a) the existing dependency among populations, b) transition
among populations, and c) the interaction with the drug.
Fig. 1 The schematic view of the system interactions. The system includes 4 types of cells: normal cells (N),
wild tumor cells (T), mutated tumor cells (TM), and drug resistant tumor cells (TR). The population of normal,
wild tumor and mutated tumor cells decreases as they interact with the drug. As the wild tumor cells
divide, they can create mutated tumor cells or resistant tumor cells. As the mutated tumor cells interact
with the drug, they can partially die and partially be transformed to resistant cells induced by the utilized
anti-cancer drug
(2d)
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The values of the parameters associated to the growth of tumor cells are tumor-
specific. Also, previously reported measurements show that the obtained values from
participants in clinical trials may also be different from those obtained from in vivo
experiments [24]. The current work has no concentration on a specific type of tumor.
However, the values of the parameters we have chosen are in the range with those
reported by other studies. For parameters with no specific reported values, ad hoc
values have been chosen. The goal is to analyze the behavior of the system under these
specifically chosen cases. Below, the choice of parameters has been explained with
further details.
Two parameters that describe the growth are the growth rate and the carrying capacity.
Other studies have reported a value of less than one for the growth rate, and a carrying
capacity between 105 cells and 109 cells [15, 25]. However, it should be noted that the
value of the carrying capacity is organs-specific [26]. To be in this range, the adapted
values in this study are KM = KT = KN = Kr = 10
6 (cells), rT = rR = rM =0.25 (day
−1), rN = 0.5
(day−1). To choose the value of T*, we referred to the reported study of Demicheli et al.
[27], which explains that more information is available on the initial and last stages of the
tumor growth than on tumor growth in the intermediate phase. The study explains that
the growth pattern in the intermediate phase is very complex and tumor specific. The
critical tumor cell size of human colon carcinoma cell line "LoVo," where the pattern of
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The description of parameters are: τ2: Mutation rate of wild tumor cells to tumor cells with the gene that can potentially go
through second mutation to drug-resistant cells as they interact with the drug. τM→ R: Mutation/ conversion rate of mutated
tumor cells with targeted gene to drug-resistant tumor cells. τ1: Mutation rate of wild tumor cells to drug-resistant tumor cells.
Specifications of Drug I (Effective on wild and mutated tumor cells). Specifications of Drug II (Effective on drug resistant tumor
cells). Also, the common parameters related to the tumor growth are: KN, KT, K R: the carrying capacity of normal cells and
two types of tumor cells. The per capita growth rate for the drug-responsive tumor cells, two groups of drug-resistant tumor
cells, and normal cells are expressed by rT, rR, rM, rN. The T* is the critical size of the collection of tumor cells. κ is the parameter
expresses interaction between tumor and normal cells
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growth deviated from the Gomertizian, was measured to be in the intermediate phase of
growth when the tumor cell population was approximately 103 cells [27]. Relying on the
findings of this study, and since the carrying capacity (the last phase of growth) in the
current work is set to be 106 cell, T* has been chosen to be 105 cells, to be placed in the
intermediate growth phase.
The parameters related to the chemotherapeutic agents are: the death rate of the
tumor cells induced by the drug, the drug concentration and, accordingly, toxicity coef-
ficient, and the drug pharmacokinetics parameters. The induced death rate for drug
sensitive tumor cells aTR and aT (0.15 day
−1) are considered to be equal, and the order
of the value of these parameters is consistent with those reported by previous studies
[15]. Also, the two parameters are associated to the chemotherapeutic agent: "M", the
pharmacokinetics parameters with a value of 1, and C, the drug concentration or
toxicity coefficient [24]. We first evaluated the cases when the drug concentration
remains constant (C = 0.2 mg.m−2) in the tumor site. Then, the dynamic of the cell
populations was evaluated in cases in which the amount of the chemotherapeutic agent
went under decay in the tumor site. This decay was considered to be exponential with
the drug decaying rate of 10−3 day−1. The value for the decaying parameter is an ad hoc
value and is case based.
The value of the parameters related to the transition of the cells from one sub-
population to another are also ad hoc values. These transitions include those from wild
tumor cells to resistant tumor cells; wild tumor cells to mutated tumor cells that can
be converted to resistant tumor cells as they interact with the drug; and mutated tumor
cells to resistant tumor cells. The method of measurement of the rates of these
mutations and transitions is being explored. Therefore, the evaluation of the dynamic
of the system is limited to the case study with some ad hoc values. The selected values
for these parameters are reflected in Table 1.
Under this general method of choosing parameters, different values are considered
for the parameters that are linked to the therapeutic approaches. The outcomes of sim-
ulations under these choices are discussed below.
Results and Discussion
Numerical simulations under different therapeutic approaches
Constant drug and drug-induced resistance
Under the first therapeutic approach, it is assumed that the drug is administered at
t = 50 days. The amount of the drug and the killing rates are considered to be
constant. It is also considered that as the drug is introduced, the mutation to the
second group of tumor cells, TM, starts immediately at the rate of 10
−3 per day.
Part of the population of the mutated tumor cells will then be transformed into re-
sistant tumor cells. However, as they are still responsive to the drug, another part
dies due to the toxic effect of the drug. Those that remain will grow and create
new cells that carry the mutated gene, which potentially can create drug-induced
resistance. The outcome of the simulation expressed in Fig. 2a shows that the
population of mutated tumor cells and wild tumor cells have been successfully
controlled in the time frame of simulation (t = 500 days). They both die out of the
system. The drug-resistant tumor cells are initiated and grow as well.
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In our work, a Gompertzian model is considered for the growth of cells with the
chosen value for the carrying capacity equal to106 cells. Therefore, the critical point of
the growth, when the cells enter a slower phase of growth, is around 2*105 cells. This
critical point is considered as a point when tumor population becomes clinically
detectable [28]. In such a case, around t = 375 days, their populations can be detectable.
However, they immediately grow and become the dominant population at the end of
the simulation time, t = 500 days. Figure 2b evaluates the clinically observed cases when
the drug-induced resistant tumor cells mutate as the wild tumor cells interact with the
administered drug for a long time. Distinct from Fig. 2a, in this simulation, it is
assumed that the transformation of the mutated tumor cells to resistant cells starts at
the later time of t = 150 days. The shrinkage of drug-responsive tumor cells can be
seen. In this case, the population of drug-resistant tumor cells is not yet dominant at
the end of the simulation.
Decaying drug and drug-induced resistance
In Fig. 2c, the therapy with anti-cancer drug starts at t = 50 days. However, the amount of
the drug will not stay constant and decreases exponentially over time, with a decay factor
of 10−3 day−1. At t = 450 days, the drug-resistant tumor cells become detectable, and at
the end of the simulation time, they are not dominant tumor cells. The population of





Fig. 2 Dynamic of Cells under Different Therapeutic Strategies. This figure expresses the evaluation patterns of
normal cells (black line), Wild tumor cells that are responsive to the drug (orange line), Mutated tumor cells which
can potentially convert to drug-resistant tumor cells while responsive to the drug (blue line), and drug-resistant
tumor cells (red line). a: Under the first therapeutic approach, it is assumed that the drug is administered at
t = 50 days. The amount of the drug and the killing rates are considered to be constant. It is also considered that
as the drug is introduced, the mutation to the second group of tumor cells, TM, starts immediately at the rate of
10−3 per day. Distinct from the a, in the simulation b, it is assumed that the transformation of the mutated tumor
cells to resistant cells starts at the later time of t = 150 days. In c, the therapy with anti-cancer drug starts at
t = 50 days. However, the amount of the drug will not stay constant and decreases exponentially over time, with a
decay factor of 10−3 day−1. The simulation d evaluates the case when the system expresses an intrinsic drug
resistance, in addition to an induced drug resistance with the mutation rate of wild tumor cells to drug-resistant
tumor cells of 10−4 per day
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In the current case, as the simulation shows, some wild and mutated tumor cells still
exist in the system. As they are responsive to the drug, the treatment can be continued.
The drug-resistant tumor cells were created with a delay, as compared with the pre-
vious case when the amount of the drug was constant, and the growth of drug-resistant
tumor cells occurred earlier.
It should be noted that in some cases, detecting drug resistance can be an advantage,
as the therapeutic approach can be altered accordingly. By switching to another drug
or by utilizing a combination therapy, there can be a path to a more successful treat-
ment. This, certainly, is a therapeutic choice, depending on many health factors of the
given patient.
Intrinsic and drug-induced resistance
The simulation 2 d evaluates the case when the system expresses an intrinsic drug
resistance, in addition to an induced drug resistance.
One of the therapeutic approaches to controlling intrinsic drug resistance is the use
of a higher dosage of a drug in early stages of the cancer progression. Under the simu-
lation conditions, it is assumed that two types of drugs are implemented, one with a
higher dosage that is toxic to drug-resistant cells. The amount of this drug is consid-
ered to stay constant over time. The second drug is toxic to tumor-responsive cells.
The amount of this drug decays exponentially over time. The result of this simulation
shows that this approach is effective in overcoming drug-resistant tumor cells. By the
end of the simulation time, they die out of the system and the remaining tumor cells
are responsive to the drug. In such a case, tailoring the therapy to achieve the best out-
come is again a factor of concern. As there are still some drug-responsive tumor cells
in the system, the treatment with the second drug can be continued. However, since
the drug-resistant tumor cells have died out of the system, the treatment with the first
drug can be terminated. The continuation of the treatment with the second drug,
which is effective on drug responsive cells, raises the possibility of the creation of
another drug-resistant tumor cell. It is possible that periodic treatments could be a
more successful therapeutic approach to control both the progression of cancer as well
as the existing resistance.
Conclusions
Cancer drug resistance, which is an obstacle to successful treatment outcomes, is not
limited to intrinsic resistance. The success of the treatment becomes more unpredic-
table if the introduced drug induced some resistance. The utilization of different che-
motherapeutic drugs, combination therapy, and periodic therapy are some protocols
that are currently implemented. The use of modeling and computer simulations en-
hance our understanding of the evolution patterns that may occur during treatments.
In the present study, the evolution of the cells in a conjoint setting, when the system
expresses both intrinsic and induced resistance, is mathematically modeled. Followed
by a set of computer simulations, the different growing patterns that can be created
based on choices of therapy were examined. The model can still be improved by
considering the nature of the cancer growth: for example, it would be more realistic to
include such things as the blood supply, the three dimensionality of the growth, and
other important biological variables.
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Some open concerns include whether the mutations happen at a constant rate or if
the rate can be affected by the drug and other surrounding conditions. Furthermore, in
all of these cases, the level of toxicity that the body can tolerate, along with other fac-
tors such the strength of the patient’s immune system, play important roles in making
decisions with regards to impactful therapy.
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